119 related articles for article (PubMed ID: 15717631)
1. IgM-anticardiolipin antibody and vascular access thrombosis in chronic hemodialysis patients.
Chuang FR; Chen TC; Yang CC; Cheng YF; Hsu KT; Lee CH; Lin CL; Wang IK; Chang HW; Wang PH
Ren Fail; 2005; 27(1):25-30. PubMed ID: 15717631
[TBL] [Abstract][Full Text] [Related]
2. Anticardiolipin antibody and Taiwanese chronic haemodialysis patients with recurrent vascular access thrombosis.
Chuang FR; Chang HW; Lin CL; Wang IK; Chang HY; Wang PH; Yang CC; Chen TC; Wu CS; Lee CH
Int J Clin Pract; 2005 Jul; 59(7):785-90. PubMed ID: 15963205
[TBL] [Abstract][Full Text] [Related]
3. Anticardiolipin antibodies and vascular access thrombosis in Taiwanese haemodialysis patients with chronic hepatitis C: a retrospective study.
Lee CH; Wang IK; Chen TC; Chang HW; Yang CC; Chien YS; Wu CS; Chiou TT; Wu MS; Wang PH; Chuang FR
Int J Clin Pract; 2006 Dec; 60(12):1591-5. PubMed ID: 16704678
[TBL] [Abstract][Full Text] [Related]
4. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis.
Adler S; Szczech L; Qureshi A; Bollu R; Thomas-John R
Clin Nephrol; 2001 Dec; 56(6):428-34. PubMed ID: 11770794
[TBL] [Abstract][Full Text] [Related]
5. Anticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failure.
Ozmen S; Danis R; Akin D; Batun S
Clin Nephrol; 2009 Sep; 72(3):193-8. PubMed ID: 19761724
[TBL] [Abstract][Full Text] [Related]
6. The relationship between anticardiolipin antibodies and vascular access occlusion in patients on hemodialysis.
Gültekin F; Alagözlü H; Candan F; Nadir I; Bakici MZ; Sezer H
ASAIO J; 2005; 51(2):162-4. PubMed ID: 15839442
[TBL] [Abstract][Full Text] [Related]
7. [Anticardiolipin antibodies in hemodialysis patients and in renal transplant recipients: prevalence and significance].
Ferlazzo B; Barrile A; Bonanno D; Quattrocchi P; Santoro D; Savica V; Bellinghieri G
Recenti Prog Med; 1998 Sep; 89(9):434-7. PubMed ID: 9796372
[TBL] [Abstract][Full Text] [Related]
8. Hyperhomocysteinaemia and vascular access thrombosis among chronic hemodialysis patients in Taiwan: a retrospective study.
Chen TC; Wang IK; Lee CH; Chang HW; Chiou TT; Lee CT; Fang JT; Wu MS; Hsu KT; Yang CC; Wang PH; Chuang FR
Int J Clin Pract; 2006 Dec; 60(12):1596-9. PubMed ID: 16704682
[TBL] [Abstract][Full Text] [Related]
9. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients.
Manns BJ; Burgess ED; Parsons HG; Schaefer JP; Hyndman ME; Scott-Douglas NW
Kidney Int; 1999 Jan; 55(1):315-20. PubMed ID: 9893142
[TBL] [Abstract][Full Text] [Related]
10. Anti-cardiolipin, anti-endothelial-cell and anti-malondialdehyde-LDL antibodies in uremic patients undergoing hemodialysis: relationship with vascular access thrombosis and thromboembolic events.
George J; Aron A; Levy Y; Gilburd B; Ben-David A; Renaudineau Y; Zonana-Nachach A; Youinou P; Harats D; Shoenfeld Y
Hum Antibodies; 1999; 9(2):125-31. PubMed ID: 10405833
[TBL] [Abstract][Full Text] [Related]
11. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients.
Valeri A; Joseph R; Radhakrishnan J
Clin Nephrol; 1999 Feb; 51(2):116-21. PubMed ID: 10069647
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein predicts vascular access thrombosis in hemodialysis patients.
Chou CY; Kuo HL; Yung YF; Liu YL; Huang CC
Blood Purif; 2006; 24(4):342-6. PubMed ID: 16601326
[TBL] [Abstract][Full Text] [Related]
13. Antiphospholipid (aPL) antibodies in end-stage renal disease.
Fabrizi F; Sangiorgio R; Pontoriero G; Corti M; Tentori F; Troina E; Locatelli F
J Nephrol; 1999; 12(2):89-94. PubMed ID: 10378664
[TBL] [Abstract][Full Text] [Related]
14. The association between pulse pressure and vascular access thrombosis in chronic hemodialysis patients.
Chou CY; Liu JH; Kuo HL; Liu YL; Lin HH; Yang YF; Wang SM; Huang CC
Hypertens Res; 2009 Aug; 32(8):712-5. PubMed ID: 19590503
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine and vascular access thrombosis in end-stage renal disease patients: a retrospective study.
Bowden RG; Wyatt FB; Wilson R
J Nephrol; 2002; 15(6):666-70. PubMed ID: 12495281
[TBL] [Abstract][Full Text] [Related]
16. Are the anticardiolipin antibodies a risk factor for coronary artery disease in chronic renal failure patients?
Ucar E; Kuvandik G; Sert M; Kuvandik C; Temizkan A; Borazan A
Ren Fail; 2008; 30(8):791-5. PubMed ID: 18791953
[TBL] [Abstract][Full Text] [Related]
17. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis.
Prakash R; Miller CC; Suki WN
Am J Kidney Dis; 1995 Aug; 26(2):347-52. PubMed ID: 7645540
[TBL] [Abstract][Full Text] [Related]
18. Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon.
Rodriguez VE; Gonzalez-Pares EN; Rivera C
P R Health Sci J; 2006 Dec; 25(4):307-13. PubMed ID: 17550096
[TBL] [Abstract][Full Text] [Related]
19. Study of anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with ischemic stroke.
Cojocaru IM; Cojocaru M; Muşuroi C; Botezat M
Rom J Intern Med; 2003; 41(2):189-204. PubMed ID: 15526503
[TBL] [Abstract][Full Text] [Related]
20. Arteriovenous fistula thrombosis in patients on regular hemodialysis: a report of 171 patients.
Roozbeh J; Serati AR; Malekhoseini SA
Arch Iran Med; 2006 Jan; 9(1):26-32. PubMed ID: 16649374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
